Bullzeye FinancialCohance Lifesciences Ltd.
NSE: COHANCE · Healthcare
FDA compliance risk at key facility and 54% promoter pledge create active downside catalysts; recent 46.5% profit collapse and low-volume…
Stock recovered 52.85% from 52-week lows with RSI at 55 (neutral-to-bullish) and price above short-term EMAs, suggesting early-stage recovery from distressed valuations if FDA remediation succeeds.
Confirmed FDA Form 483 observations at critical API facility and 54.36% promoter pledge create forced-selling risk if stock declines 15-20%; recent 46.5% YoY profit collapse indicates pre-existing operational stress.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bearish 28 Sep 2026 → now Scores 28 Oct 2026₹453.30 → ₹453.30 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →